Drug intelligence / Profile preview

CL25216

Development stage: Unknown
Lead developer: ApexCPG
Administration: Oral

Overview

CL25216 is a **herbal supplement** being evaluated for its efficacy in reducing **vasomotor symptoms** (such as hot flashes) in women during perimenopause. The product is formulated as a capsule containing 250 mg of a proprietary herbal composition, taken once daily for 105 days. The supplement aims to improve quality of life and reduce perimenopausal hot flashes. Safety, tolerability, and laboratory markers are assessed during clinical trials. The exact herbal ingredients and mechanism of action are not disclosed in the available data[1][3].

Beyond the preview

Go deeper on CL25216.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CL25216.

Explore the full profile